Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31215568 | 0.88 | RIPK1 (0.52) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL12652580 | 0.81 | SCD (0.50) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL11334470 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| Water SCHEMBL27718168 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL137699 | 0.78 | HTT (0.45) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL13996301 | 0.78 | MAOB (0.45) | ALDH1A1HTTCA2DYRK1AKMT2A | |
| SCHEMBL1636840 | 0.78 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL15794568 | 0.78 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| Nitrogen SCHEMBL28651597 | 0.77 | ALDH1A1 (0.94) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 | |
| SCHEMBL11157181 | 0.77 | DYRK1A (0.64) | SMN1; SMN2ALDH1A1CYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238406-A1 | FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-3658544-B1 | DERIVATIVES OF LUCIFERIN AND METHODS FOR THEIR SYNTHESIS | UNIV CAPE TOWN (ZA) | 2024-07-31 | — | — | EP | disclosed |
| US-11149034-B2 | Derivatives of luciferin and methods for their synthesis | UNIVERSITY OF CAPE TOWN (ZA) | 2021-10-19 | — | — | US | disclosed |
| US-11149034-B2 | Derivatives of luciferin and methods for their synthesis | UNIVERSITY OF CAPE TOWN (ZA) | 2021-10-19 | — | — | US | disclosed |
| US-20200331902-A1 | DERIVATIVES OF LUCIFERIN AND METHODS FOR THEIR SYNTHESIS | UNIVERSITY OF CAPE TOWN (ZA) | 2020-10-22 | — | — | US | disclosed |
| US-20200331902-A1 | DERIVATIVES OF LUCIFERIN AND METHODS FOR THEIR SYNTHESIS | UNIVERSITY OF CAPE TOWN (ZA) | 2020-10-22 | — | — | US | disclosed |
| EP-3658544-A1 | DERIVATIVES OF LUCIFERIN AND METHODS FOR THEIR SYNTHESIS | University of Cape Town (ZA) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019021202-A1 | DERIVATIVES OF LUCIFERIN AND METHODS FOR THEIR SYNTHESIS | UNIVERSITY OF CAPE TOWN (ZA) | 2019-01-31 | — | — | WO | disclosed |
| US-8586759-B2 | Methods and systems for synthesis of a D-aminoluciferin precursor and related compounds | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586759-B2 | Methods and systems for synthesis of a D-aminoluciferin precursor and related compounds | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110224442-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (LLNS) | 2011-09-15 | — | — | US | disclosed |
| US-20110224442-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (LLNS) | 2011-09-15 | — | — | US | disclosed |
| US-20110213124-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2011-09-01 | — | — | US | disclosed |
| US-20110213124-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2011-09-01 | — | — | US | disclosed |
| US-20110213124-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2011-09-01 | — | — | US | disclosed |
| WO-2009014674-A1 | HETEROCYCLYLAMIDES AS GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331902-A1 | DERIVATIVES OF LUCIFERIN AND METHODS FOR THEIR SYNTHESIS | GLB1, DBNL, GLO1 | SMN1; SMN2 4829/4885ALDH1A1 747/4885CYP3A4 724/4885 |
| US-20110224442-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | HCCS, HLCS, GLUL | SMN1; SMN2 4724/4885ALDH1A1 2394/4885CYP3A4 754/4885 |
| US-20110213124-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | HCCS, HLCS, GLUL | SMN1; SMN2 4724/4885ALDH1A1 2394/4885CYP3A4 754/4885 |
| US-11149034-B2 | Derivatives of luciferin and methods for their synthesis | GLB1, DBNL, GLO1 | SMN1; SMN2 4829/4885ALDH1A1 747/4885CYP3A4 724/4885 |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | SMN1; SMN2 4591/4885ALDH1A1 983/4885CYP3A4 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.